China's Growth Hormone Treatment Market Is Booming

by Grace Wang Aug 15, 2022

China has a huge market for growth hormone products, which are needed by around 7 million Chinese children for the treatment of short stature. The market is expanding as people are paying more attention to short stature disorder. 

In 2018, China's growth hormone market size was 0.6 billion USD. With an estimated compound annual growth rate (CAGR) of 15.7% from 2018 to 2030, the market size is expected to reach 3.2 billion USD by 2030.1

Growth Hormone Market Shares in China

In China, the approved growth hormone products have three dosage forms:

  1. Short-acting powder for injection;

  2. Short-acting solution for injection;

  3. Long-acting solution for injection.

GeneScience Pharmaceutical (GenSci) is the only company that can supply all the three types of products in China. It is also the leading company in terms of market share, which reached 76.13% in 2020, followed by Anhui Anke Biotechnology (12.48%) and Shanghai United Cell Biotechnology (8.81%). Other Chinese companies (e.g., Zhongshan Sinobioway Hygene Biomedicine) and two international companies (Novo Nordisk and LG Chem) altogether accounted for about 3% market share.2

baipharm-china-growth-hormone-market-shares-1.pngChina Growth Hormone Market Shares in 2020, data source: chinabaogao.com

GenSci takes the lead due to the following reasons:

  • GenSci has accumulated sufficient clinical data to prove its safety and effectiveness as its first growth hormone product was approved early in 1998.

  • Once patients choose to use the product, they need to keep using it for a long time—16 months in average.3

  • Hospitals prefer to use products with reliable and sufficient safety data. Some hospitals allow no more than two oral products and two injections under the same generic name, which limits multiple competitor products to be sold at the same hospital.

  • GenSci owns the most competitive growth hormone products with standards higher than those of international companies. Its Recombinant Human Growth Hormone Injection currently has 11 approved indications, 9 of which are related to short stature or slow growth. Its Polyethylene Glycol Recombinant Human Growth Hormone Injection is the only approved long-acting growth hormone product in China.

  • GenSci has also made other efforts, e.g., developing sales channels in addition to public hospitals, increasing expenditure on research and sales, etc.

GenSci's Growth Hormone Products Approved in China

Name

Dosage Form

Approval Year

Recombinant Human Growth Hormone Injection

Powder for Injection

1998

Solution for Injection

2005

Polyethylene Glycol Recombinant Human Growth Hormone Injection

Long-acting Solution for Injection

2014

Market Trend: Long-acting Solution for Injection May Gain More Shares

Since 2017, the short-acting solution for injection has been continuously increasing in terms of market share. Though long-acting solution for injection takes a tiny market share of less than 1% in 20204, it has promising future because it can be injected less frequently with high levels in safety and efficacy.

baipharm-market-shares-of-different-dosage-forms-of-growth-hormone-products-from-2015-2020.pngMarket Shares of Different Dosage Forms of Growth Hormone Products from 2015-2020, data source: PDB Database, chyxx.com

Many companies are actively developing long-acting products and approaching the marketing stage. For example, Anke Biotech's PEGylated Recombinant Human Growth Hormone Injection and Visen Pharmaceuticals' TransCon Growth Hormone have entered phase III clinical trials. International companies, including Pfizer and Novo Nordisk, may also market long-acting products in China. Thus, long-acting products are expected to have lower prices in the competition and larger market shares in the future.

Grace Wang
ChemLinked Regulatory Analyst & Editor
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2024 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com
You May Also Like
Most Popular